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Abstract
Although histological grade and muscular invasion are related to the malignant behaviors of
endometrial endometrioid carcinoma, lymphatic and/or distant metastases are unexpect-
edly encountered, even in patients in the low-risk group. To re-evaluate additional reliable
parameters to predict the risk of progression, we examined the immunohistochemical
expression profiles of p53 and estrogen receptor (ER) β proteins. Patients with endometrial
endometrioid carcinoma who underwent surgical treatment at our hospital (n = 154) were
recruited to this study, and the significance of the relationships between the incidence of
regional lymph node metastasis and/or postoperative recurrence and clinical or experimen-
tal parameters was evaluated. By multivariate analysis, we found that histological grades,
detection of immunoreactive p53 (positive rates more than 10%, p53-stained), and high
expression of ERβ (high-ERβ) were independently associated with metastasis and/or recur-
rence. Among these parameters, the sensitivity and negative predictive values of high-ERβ
were very high (up to 100%). In the population with high-ERβ, the positive rates of metasta-
sis and/or recurrence were 61.1% in the p53-stained group and 21.9% in the p53-non-
stained (negative) group. Furthermore, the positive rate in the group showing myometrial
invasion of more than 1/2 and showing both p53-stained and high-ERβ was 80%. The dis-
ease-free survival of patients who were double-positive for p53-stained and high-ERβ
was significantly shorter than that in other patients. In summary, our findings showed that
increases in ERβ and p53 immunoreactivity were significantly correlated with the incidence
of metastasis and/or recurrence in endometrial endometrioid carcinoma, suggesting that
double-positivity for p53-stained and high-ERβmay provide a promising clinical indicator to
predict the risk of progression.
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Introduction
Endometrial endometrioid cancer can be categorized into type-I and type-II based on clinical,
histopathological, and molecular findings [1]. Type-I endometrioid cancer is mainly com-
posed of well/moderately differentiated cells that are thought to develop in an estrogen-depen-
dent manner [2, 3, 4]. Estrogen receptor (ER) α has been reported to play an important role
in the development of estrogen-dependent malignant tumors. However, recent studies have
proposed that ERβ is also associated with gynecologic malignant tumors [5, 6]. Moreover,
researchers also demonstrated that the expression of ERβ in endometrial endometrioid carci-
noma is greater than that in the normal endometrium [5, 7] and that a high ERβ/ERα expres-
sion ratio is an independent prognostic marker of survival in patients with endometrial
endometrioid carcinoma [8]. Additionally, human endometriotic cells extracted from patients
with endometriosis exhibit higher expression of ERβ than cells extracted from patients without
endometriosis [9]. Enhanced ERβ activity has also been shown to stimulate the progression of
endometriosis through a mechanism involving escape of immune surveillance and interaction
with the inflammasome, thereby upregulating interleukin-1β in mice [10]. In type-I endome-
trial endometrioid carcinoma, dysfunction of DNA mismatch repair genes and gene mutations
in phosphatase and tensin homolog deleted from chromosome 10 (PTEN) and v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog (KRAS) have been shown to be associated with
carcinogenesis of the endometrium [11, 12, 13], whereas gene mutations in TP53 have been
reported to be associated with high-level invasive and metastatic properties of cancer cells [14,
15, 16].
Grades of cellular atypia and differentiation are clinically related to the malignant behaviors
of type-I endometrial endometrioid carcinoma [17, 18]. The depth of muscular invasion by
cancer cells is an additional important prognostic factor that has been used as a clinical crite-
rion to determine the postsurgical stage of endometrial cancers [18, 19]. Accordingly, endome-
trioid carcinoma with histological grade 1 (G1) or 2 (G2) along with muscular invasion of
less than one-half is classified into the low-risk group [20–23]. Although limited surgical
approaches may be applied to patients in low-risk groups, lymphatic and/or distant metastases
are unexpectedly encountered, resulting in undertreatment. Therefore, additional parameters
to more precisely predict the risk of metastasis are required in order to select appropriate oper-
ative procedures.
On the basis of this background, we aimed to identify useful parameters by assessing the
relationships between ERβ/p53 and clinical disease progression. In this study, we focused on
the immunohistochemical expression of ERβ and p53 protein in endometrial endometrioid
carcinoma and investigated whether both ERβ and p53 proteins were associated with the inci-
dence of regional lymph node metastasis or postoperative recurrence.
Materials and methods
Tissue samples and patients
Tumor tissues were obtained from patients who had undergone hysterectomy as a primary
surgical therapy for endometrial cancer at the Department of Obstetrics and Gynecology,
Kanazawa University Graduate School of Medical Sciences (Ishikawa, Japan) between January
2008 and December 2014. All patients were examined under a systemic imaging test to check
for distant metastases before surgery, and patients who were found to have distant metastases
pre-operatively were excluded from this study. Surgical specimens were fixed with 20% forma-
lin and embedded in paraffin. The tissue sections (4 μm) were stained by routine histopatho-
logical techniques for diagnosis. Representative tissue sections from each specimen were
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subjected to immunohistochemical examination. Fresh tumor tissues from each specimen
were frozen and stored at -80˚C until use in DNA analysis. Neither chemotherapy nor irradia-
tion therapy was performed prior to primary surgery. Patients who were diagnosed with endo-
metrioid carcinoma on postoperative pathological assessment were recruited to this study. The
surgical stage was determined in accordance with the International Federation of Gynecology
and Obstetrics (FIGO) staging. Standard surgical procedures for endometrial cancers included
hysterectomy and bilateral salpingo-oophorectomy with retroperitoneal lymphadenectomy.
Patients with cervical involvement underwent radical hysterectomy and bilateral salpingo-
oophorectomy with retroperitoneal lymphadenectomy. Combination chemotherapy or irradi-
ation therapy as postoperative adjuvant treatment was performed for all patients except for
those with stage IA and histological grade 1 or 2 (G1 or G2) disease. Clinicopathological infor-
mation and survival data were extracted from the medical records of each patient. Written
informed consent was obtained from each patient. This study and the use of human tissue
specimens were approved by the Ethics Committee of the Kanazawa University Graduate
School of Medicine.
Immunohistochemistry
Tissue localization of ERβ and p53 protein was immunohistochemically determined by the avi-
din-biotin-peroxidase complex (VECTASTAIN ABC Kit; Vector Laboratories, Burlingame,
CA, USA) method using formalin-fixed and paraffin-embedded sections, as reported previ-
ously [24]. Briefly, sections of representative blocks from each patient were deparaffinized in
xylene and rehydrated in ethanol, and antigen retrieval was subsequently performed in 0.01 M
citrate buffer (pH 6.0). The slides were immersed in 3% hydrogen peroxide for 10 min to block
endogenous peroxidase activity and then washed in 0.05 M phosphate-buffered saline (PBS,
pH 7.4). The slides were incubated with primary rabbit monoclonal antibodies against p53
protein (clone: SP5; Thermo Fisher Scientific, Runcorn, UK) at a dilution of 1:100 for 30 min
at room temperature and mouse monoclonal antibodies against ERβ (clone: PPG5/10; Bio-
Rad Laboratories, Hercules, CA, USA) at a dilution of 1:50 overnight at 4˚C in a humidified
chamber. After washing, the sections were incubated for 30 min with biotin-labeled goat anti-
rabbit IgG for p53 and horse anti-mouse IgG for ERβ at room temperature. Consequently, sec-
tions were treated with the avidin-biotin complex at room temperature. Sites of peroxidase
activity were visualized with diaminobenzidine (Liquid DAB+ Substrate Chromogen System;
Dako, Carpinteria, CA, USA), and the sections were then counterstained with hematoxylin.
The expression profile of p53 was evaluated by estimating the proportion of nuclear stain-
ing of tumor cells, as described previously [25]. Cases in which nuclear staining was observed
in at least 10% of cancer cells were classified as a p53-stained group. Immunohistochemical
staining for ERβ was evaluated based on the percentage of nuclear staining and the intensity of
staining in tumor cells, as previously reported [26]. Specifically, the cases were grouped into
low expression of ERβ protein (low-ERβ, weak nuclear staining intensity or less than 50% of
cancer cells with nuclear staining) or high expression of ERβ protein (high-ERβ, moderate/
strong nuclear staining intensity and more than 50% of cancer cells with nuclear staining).
DNA analysis of TP53 mutations
DNA was extracted from frozen tumor samples for TP53mutation screening using a QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Fol-
lowing DNA extraction, the samples were evaluated for mutations in exons 5–8 of the TP53
gene because almost all TP53 gene mutations in various cancers have been found in these
exons [27]. Isolated genomic DNA was amplified by polymerase chain reaction (PCR) using
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the primer pairs 50-TGTTCACTTGTGCCCTGACT-30 and 50-CAGCCCTGTCGTCTCTCCAG-
30 for exon 5, 50-CTGGGGCTGGAGAGACGACA-30 and 50-GGAGGGCCACTGACAACCA-30
for exon 6, 50-CTCCCCTGCCACA-30 and 50-AGGGGTCAGCGGCAAGCAGA-30 for exon 7,
and 50-GACAAGGGTGGTTGGGAGTAGATG-30 and 50-GCAAGGAAAGGTGATAAAAGTGAA-
30 for exon 8 of TP53. PCR was performed for 30 cycles at 95˚C for 1 min, 58˚C for 1 min,
and 72˚C for 1 min. After amplification, the resulting PCR products were purified with a
MinElute Gel Extraction Kit (Qiagen) or QIAquick PCR Purification Kit (Qiagen). The puri-
fied PCR products were sequenced and detected using a DNA sequencer (3730xl DNA Ana-
lyzer; Thermo Fisher Scientific).
Statistical analysis
To analyze progressive factors, chi-squared tests were performed for univariate analysis, and
regression analysis was performed for multivariate analysis (IBM SPSS Statistics version 23).
Disease-free survival among the 4 groups with p53-/ERβ low, p53+/ERβ low, p53-/ERβ high,
and p53+/ERβ high expression was analyzed by the Kaplan-Meier method.
Results
Clinical and pathological characteristics
The clinicopathological features of all patients are shown in Table 1. A total of 154 endometrial
endometrioid carcinoma cases were included in this study. Among them, 128 patients (83.1%)
were postmenopausal, 94 were International Federation of Gynecology and Obstetrics (FIGO)
stage IA, 29 were FIGO stage IB, 15 were FIGO stage II, 4 were FIGO stage IIIA, and 12 were
FIGO stage IIIC. The mean follow-up time of the 154 patients was 53 months. Regional lymph
node metastasis and/or postoperative disease recurrence was observed in 29 (18.8%) cases. In
particular, 12 (41.4%) of the 29 patients with metastasis and/or recurrence experienced para-
aortic lymph node metastases (Table 2). Two (1.3%) of the patients with FIGO stage IIIC and
histological grade 3 (G3) disease who showed myometrial invasion of at least 1/2 died of
tumor progression. Regional lymph node metastasis and/or postoperative disease recurrence
were observed in 8.3% (8/96) of patients with histological grade 1 disease and in 30.6% (11/36)
and 45.5% (10/22) of patients with grades 2 and 3 disease, respectively. The pathological data
showed that histological grade 2/3, deep myometrial invasion ( 1/2), lymph-vascular space
invasion (LVSI), detection of immunoreactive p53 (p53-stained), and high-ERβ were signifi-
cantly correlated with the incidences of regional lymph node metastasis and/or postoperative
recurrence by univariate analysis of metastatic factors (Table 3).
We then conducted multivariate analysis and selected three significant independent meta-
static factors: histological grade (G1 versus G2+G3), expression of immunoreactive p53 pro-
tein (stained versus non-stained (negative)), and expression of immunoreactive ERβ protein
(high versus low; Table 3).
Relationship between immunohistochemical detection of p53 protein
and the incidence of regional lymph node metastasis and/or recurrence
Initially, to evaluate the correlation between the significance of accumulating p53 protein and
metastatic/recurrent disease, we evaluated the expression of p53 protein in endometrial
tumors by immunohistochemistry. The p53-stained was detected in 52 (33.8%) of the 154
patients with endometrial endometrioid carcinoma. The p53-stained was significantly corre-
lated with a high histological grade (G1: 19/96 [19.8%], G2: 18/36 [50.0%], and G3: 15/22
[68.2%]) and the depth of myometrial invasion (myometrial invasion < 1/2: 26/105 [24.8%]
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and myometrial invasion 1/2: 26/49 [53.1%]). Patients showing p53-stained had a signifi-
cantly increased incidence of metastatic and/or recurrent disease than those with negative
staining. In particular, among patients with histological grade G1 or G2, the p53-stained was
associated with an increased incidence of metastatic and/or recurrent disease (p53 negative: 5/
95 [5.3%], p53-stained: 14/37 [37.8%], p< 0.01); however, no differences were observed in
patients with histological grade G3 disease (p53 negative: 2/7 [28.6%], p53-stained: 8/15
[53.3%], p = 0.27).
The sensitivity and specificity of the p53-stained for regional lymph node metastasis and/or
postoperative recurrence were 75.9% (22/29) and 76.0% (95/125), respectively, whereas the
positive and negative predictive values were 42.3% (22/52) and 93.1% (95/102), respectively
(Table 4).
Relationship between TP53 gene mutations and the incidence of
regional lymph node metastasis and/or recurrence
Next, we examined mutations in the TP53 gene, which can affect the immunohistochemical
detection of p53 protein. Among the 52 cases of p53-stained, we could not perform genetic
analysis in 12 cases due to a lack of adequate tissue samples. Consequently, genetic analysis by
direct sequencing of PCR products after electrophoresis was performed using tissue specimens
from 40 endometrioid carcinoma cases with p53-stained.
From this analysis, TP53 gene mutations were observed in 13 (32.5%) of 40 endometrioid
carcinoma cases. All of the mutations confirmed by direct sequencing were missense point
Table 1. Clinicopathological data on 154 patients with endometrial endometrioid carcinoma.
No metastasis Metastasis
n = 125 n = 29
Age 60 (24–87) 60 (36–83)
Parity 2 (0–4) 2 (0–3)
BMI 22.5 (12.9–40.2) 22.5 (15.1–31.5)


















LVSI: lymph-vascular space invasion
https://doi.org/10.1371/journal.pone.0188641.t001
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mutations (Fig 1). Among them, the positive rates were 27.3% in G1 (3/11), 31.3% in G2 (5/
16), and 38.5% in G3 (5/13), indicating that TP53 gene mutations were not significantly corre-
lated with the histological grade in endometrioid carcinoma. In addition, there were no signifi-
cant differences in the incidences of metastatic and/or recurrent disease between patients with
and without TP53 gene mutation.
Then, we further classified the percent positive ranges of p53 expression into 0–9%
(n = 102), 10–19% (n = 22), 20–49% (n = 11), 50–79% (n = 9), and 80–100% (n = 10) and re-
evaluated the relationships among p53 expression profiles, p53 mutations, and clinical out-
comes (Table 5). High-positive groups (50–79 and 80–100%) showed high rates of p53
mutation (44.4 and 83.3%, respectively), while low-positive groups (10–19 and 20–49%) dem-
onstrated low rates of p53 mutation (16.7 and 14.3%, respectively). On the other hand, the
rates of regional lymph node metastasis and/or postoperative recurrence in the low-positive
groups (10–19% group (36.4%) plus 20–49% group (45.5%), total (13/33, 39.4%)) were as high
as those of the high-positive groups (50–79% group (55.6%) plus 80–100% group (40%), total
(9/19, 47.4%)).
Table 2. Summary of the 29 cases with regional lymph node metastasis and/or postoperative recurrence of endometrial endometrioid carcinoma.
No. FIGO stage Grade MI LVSI Lymph node dissection Metastatic lymph node in surgery Postoperative metastasis
1 IA G1 <1/2 + Pelvic LN No PAN
2 IA G2 < + Pelvic LN No Liver, Cardiophrenic LN
3 IA G2 < - Pelvic LN No PAN
4 IA G2 < - Pelvic LN No PAN, Peritoneum, Omentum
5 IA G2 < - Pelvic LN No Pelvic LN
6 IA G3 < + Pelvic LN No PAN, Lung
7 IA G3 < + Pelvic LN No Lung, Bone, Mediastinal LN
8 IB G1  + Pelvic LN No Lung
9 IB G1  + Pelvic LN No PAN
10 IB G2  + No No PAN
11 IB G2  + No No Pelvic LN, Lung
12 IB G2  + No No PAN
13 IB G3  + Pelvic LN No PAN
14 II G1  + Pelvic LN No Lung
15 II G1  - Pelvic LN No Pelvic LN
16 IIIA G2  + No No PAN
17 IIIA G3  + Pelvic LN No Pelvic LN
18 IIIC G1 < - Pelvic LN Pelvic LN PAN
19 IIIC G1  + Pelvic LN Pelvic LN No
20 IIIC G1  + Pelvic LN Pelvic LN PAN
21 IIIC G2 < - Pelvic LN Pelvic LN Lung
22 IIIC G2  + Pelvic LN Pelvic LN No
23 IIIC G2  + Pelvic LN-PAN Pelvic LN Lung
24 IIIC G3  + Pelvic LN-PAN Pelvic LN Lung, Peritoneum
25 IIIC G3  + Pelvic LN Pelvic LN No
26 IIIC G3  + Pelvic LN-PAN Pelvic LN Peritoneum
27 IIIC G3  + Pelvic LN-PAN Pelvic LN, PAN Bone, Lung, Peritoneum
28 IIIC G3  + Pelvic LN Pelvic LN Peritoneum
29 IIIC G3  + Pelvic LN Pelvic LN No
MI, muscular invasion; LVSI, lymph-vascular space invasion; LN, lymph node; PAN, para-aortic lymph node.
https://doi.org/10.1371/journal.pone.0188641.t002
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Relationship between the expression intensity of immunoreactive ERβ
and the incidence of regional lymph node metastasis and/or recurrence
To evaluate the clinical significance of ERβ expression in endometrial endometrioid carci-
noma, we examined the immunohistological expression profiles of ERβ protein. Immunohis-
tochemical localization of ERβ and p53 proteins in representative cases of endometrial
endometrioid carcinoma is shown in Fig 2. High expression of ERβ was significantly correlated
with a high histological grade (G1: 35/96 [36.5%], G2: 16/36 [44.4%], G3: 17/22 [77.3%])
and deep myometrial invasion (myometrial invasion < 1/2: 34/105 [32.4%] and myometrial
invasion 1/2: 34/49 [69.4%]).
The sensitivity and negative predictive values of high expression of ERβ for regional lymph
node metastasis and/or postoperative recurrence were both 100% (29/29 and 86/86, respec-
tively), whereas the specificity and positive predictive values were 68.8% (86/125) and 42.6%
(29/68), respectively (Table 4).
Table 3. Univariate and multivariate analysis of factors affecting disease progression in 154 patients with endometrial endometrioid carcinoma.
Metastasis Univariate P-value Multivariate P-value
Histological grade
G1 8/96 (8.3%)
G2 11/36 (30.6%) <0.01




1/2 20/49 (40.8%) <0.01 0.088
LVSI
Negative 6/81 (7.4%)
Positive 23/73 (31.5%) <0.01 0.55
p53
Negative 7/102 (6.9%)
Stained 22/52 (42.3%) <0.01 0.014
ERβ
Low 0/86 (0%)
High 29/68 (42.6%) <0.01 <0.01
LVSI, lymph-vascular space invasion.
https://doi.org/10.1371/journal.pone.0188641.t003
Table 4. Association of p53/ERβ expression and muscular invasion with the incidence of regional lymph node metastasis and/or postoperative
recurrence in patients with endometrial endometrioid carcinoma.
Myometrial invasion
p53 / ERβ <1/2 1/2 Total
- / low 0/61 (0%) 0/9 (0%) 0/70 (0%) a
+ / low 0/10 (0%) 0/6 (0%) 0/16 (0%) b
- / high 3/18 (16.7%) 4/14 (28.6%) 7/32 (21.9%) b,c
+ / high 6/16 (37.5%) 16/20 (80.0%) 22/36 (61.1%) a,c
a,b and c: p<0.01
https://doi.org/10.1371/journal.pone.0188641.t004
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Among the population with high-ERβ, the positive rates of regional lymph node metastasis
and/or postoperative recurrence were 61.1% in the p53-stained group and 21.9% in the
p53-non-stained group (Table 4). The positive rate in the p53-stained group was significantly
higher than that in the other groups (Table 4). When we added information on the depth of
muscular invasion, the positive rate of the group showing myometrial invasion of at least 1/2
and showing both p53-stained and high-ERβ was 80% (Table 4).
Kaplan-Meier survival analysis showed that disease-free survival in patients with p53-
stained and high-ERβ (p53+/ERβhigh) was significantly shorter than that in other patient
groups (Fig 3). The disease-free survival of patients with p53-/ERβhigh was significantly
shorter than that of patients with p53-/ERβlow and p53+/ ERβlow. Patients with p53+/
ERβhigh showed significantly shorter disease-free survival than those with p53-/ERβhigh.
Fig 1. DNA sequence analysis of the TP53 gene in cases of endometrial endometrioid carcinoma.
Representative results of sequencing of exon 8 in the TP53 gene are shown. The upper panel shows a case
of grade 3 endometrioid carcinoma with para-aortic lymph node metastasis and the wild-type sequence for
reference (A). The lower panel shows a case of grade 2 endometrioid carcinoma without metastasis and a
single nucleotide substitution, cytosine (C) to thymine (T), resulting in an arginine to cysteine substitution at
codon 273 of the TP53 gene (B).
https://doi.org/10.1371/journal.pone.0188641.g001
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Discussion
In the present study, we showed that expression of immunoreactive ERβ and p53 proteins was
associated with the incidence of regional lymph node metastasis and/or postoperative recur-
rence. To the best of our knowledge, this is the first report to demonstrate a positive correla-
tion between the co-expression of ERβ with p53 protein and clinical outcomes in patients with
endometrial endometrioid carcinoma.
Previous reports showed that positive immunostaining for p53 is associated with an
increased risk of relapse in patients with low-risk stage I endometrioid endometrial carcinoma
[28]. Moreover, p53 mutation is associated with a poor prognosis in patients with endometrial
cancer [14, 29]. In accordance with these reports, we found that the positive rate of immuno-
histochemical staining of p53 protein was significantly higher in patients with regional lymph
node metastasis and/or postoperative recurrence than in those without metastatic and/or
recurrent disease. To confirm the correlation between the immunohistochemical expression of
p53 protein and TP53 gene mutations, we analyzed the sequences of the established hot-spot
areas of the TP53 gene in patients with p53-stained. However, unexpectedly, our analysis
Table 5. Association of positive ranges of p53 expression, TP53 gene mutation, and the incidence of regional lymph node metastasis and/or post-
operative recurrence in patients with endometrial endometrioid carcinoma.
% of p53 expression No metastasis Metastasis Total mutation
Cases Mutation Cases Mutation
0–9% 95 N/A 7 (6.9%) N/A N/A
10–19% 14 2/12 (16.7%) 8 (36.4%) 1/6 (16.7%) 3/18 (16.7%)
20–49% 6 1/2 (50.0%) 5 (45.5%) 0/5 (0%) 1/7 (14.3%)
50–79% 4 3/4 (75.0%) 5 (55.6%) 1/5 (20.0%) 4/9 (44.4%)
80–100% 6 3/4 (75.0%) 4 (40.0%) 2/2 (100%) 5/6 (83.3%)
Total 125 9/22 (40.9%) 29 (18.8%) 4/18 (22.2%) 13/40 (32.5%)
Incidence of metastatic and/or recurrent disease: 0–9 vs. 10–19%, p<0.01. 10–19 vs. 20–49%, NS. 20–49 vs. 50–79%, NS. 50–79 vs. 80–100%, NS. 10–19
vs. 80–100%, NS.
N/A, not available. NS, not significant.
https://doi.org/10.1371/journal.pone.0188641.t005
Fig 2. Immunohistochemical localization of ERβ and p53 proteins in representative cases of
endometrial endometrioid carcinoma. A and B, Grade 1 endometrial endometrioid carcinoma with low-
ERβ (A) and non-stained-p53 (B). C and D, Grade 2 endometrial endometrioid carcinoma with low-ERβ and
p53-stained (D). E and F, Grade 1 endometrial endometrioid carcinoma with high-ERβ (E) and non-stained-
p53 (F). G and H, Grade 2 endometrial endometrioid carcinoma with high-ERβ (G) and p53-stained (H). Scale
bars, 100 μm.
https://doi.org/10.1371/journal.pone.0188641.g002
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confirmed genetic alterations in TP53 in only 30% of cases with p53-stained. In addition, there
were no significant correlations between TP53 gene mutations and the incidence of regional
lymph node metastasis and/or postoperative recurrence in our cases. Although the detection
of accumulated immunoreactive p53 protein in cancer cells by immunohistochemical staining
is an established method suggesting the dysfunction of p53 protein [30], our present findings
indicated that the observation of positive staining of immunoreactive p53 protein was clini-
cally more effective than the detection of TP53 gene mutations. Theoretically, the accumula-
tion of p53 protein in cancer cells can be explained by not only gene mutations but also
dysregulation of the factors that mediate metabolic or functional cascades involving p53 pro-
tein [31]. To support this speculation, when we further classified the p53-stained group into a
low-positive group (10–49%) and high-positive group (50–100%), the low-positive group had
a low rate of TP53 gene mutation in spite of a high incidence rate of regional lymph node
metastasis and/or postoperative recurrence (Table 5). Considering that the rate of metastasis
of the negative group (0–9%) was low (6.9%), these findings suggest that low-positive popula-
tions (10–49%) can be classified as a novel high-risk group based on a different perspective
from TP53 gene mutation. Further investigation of these associated factors is necessary to
understand the clinical significance of the positive expression of p53 protein in patients with
uterine endometrioid carcinoma with poor prognoses.
Importantly, in this study, despite the significance of p53 protein, approximately 25% of
cases with regional lymph node metastasis and/or recurrent disease did not express immuno-
reactive p53 protein. Considering that TP53 gene mutant tumors also show the null phenotype
of immunoreactive p53 expression, it should be noted that the immunohistochemical detec-
tion of p53 protein alone may not be sufficient to predict the risk of regional lymph node
metastasis and/or postoperative recurrence.
The differentiation of human endometrium is mainly regulated by estrogen and progester-
one [32]. Estrogen can act on the endometrium through two main ER isoforms, ERα and ERβ.
Fig 3. Disease-free survival curve of patients with p53-/ERβlow, p53+/ERβlow, p53-/ERβhigh, or p53
+/ERβhigh in endometrial endometrioid carcinoma. Disease-free survival was significantly shorter in
patients with p53-stained and high-ERβ (p53+/ERβhigh) than in other patients. Kaplan-Meier survival analysis
showed that the disease-free survival of patients with p53-/ERβhigh was significantly shorter than that of
patients with p53-/ERβlow and p53+/ERβlow. Patients with p53+/ERβhigh showed significantly shorter
disease-free survival than those with p53-/ERβhigh (**: p < 0.01).
https://doi.org/10.1371/journal.pone.0188641.g003
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Although ERβ has been suggested to coordinately play an important role in maintaining the
normal function of the endometrium together with ERα, the precise physiological roles of ERβ
in endometrial function remain unclear [33]. Similarly, the possible involvement of ERβ in the
carcinogenesis of endometrial carcinoma is still being debated [5, 7, 34]. Recently, an abnor-
mal balance between the two ER subtypes was suggested to be involved in carcinogenesis,
tumor invasion, and poor clinical outcomes in patients with gynecologic malignant tumors [8,
35]. Additionally, the expression of ERβ protein was reported to be higher in endometrial
endometrioid carcinoma than in the normal endometrium [5, 7]. Furthermore, a high ERβ/
ERα expression ratio was observed in metastatic lesions and was found to be associated with a
poor prognosis [36]. Based on the assessment criteria reported by Konstantinopoulos et al.
[26], our study showed that high expression of ERβ was significantly correlated with the inci-
dence of regional lymph node metastasis and/or postoperative recurrence. Notably, more than
80% of patients included in this study developed endometrioid carcinoma after menopause,
suggesting that estrogen may not play an important role in the progression of endometrioid
carcinoma. Consequently, the possible presence of an estrogen-independent function of ERβ
or other intranuclear proteins with similar immunoreactivity as ERβ protein may explain this
association between ERβ expression and clinical progression.
Standard operating procedures for the surgical treatment of endometrial cancer include
abdominal or laparoscopic hysterectomy and bilateral salpingo-oophorectomy with or without
pelvic and para-aortic lymphadenectomy. Because the optimal operating procedure is selected
based on pre- and intra-operative evaluations [37–41], determination of suitable clinical
parameters to predict the risk of regional lymph node metastasis and/or postoperative recur-
rence is needed. These parameters are also helpful when determining the appropriate postop-
erative adjuvant therapy. Although the number of samples is limited, the calculated sensitivity
(100%) and negative predictive value of high expression of ERβ for regional lymph node
metastasis and/or postoperative recurrence are very promising. In the population with high
ERβ expression, the positive rates of regional lymph node metastasis and/or postoperative
recurrence were 61.1% in the p53-positive group and 21.9% in the p53-negative group
(Table 4). In this regard, double-positive expression of immunoreactive ERβ and p53 proteins
may become an excellent clinical parameter to predict future risk since they can be examined
prior to surgery using cancer tissue samples obtained through pre-operative endometrial
biopsy.
Some reports have described the relationships between ERβ and p53 at the molecular level.
Indeed, studies have shown that ectopic expression of ERβ does not change the levels of p53 in
MCF10A cells, indicating that ERβ has no direct effect on the expression of p53 in the context
of the DNA damage response [42]. In contrast, other studies have reported that mutant p53 is
strongly induced in p53-mutated colon cancer SW480 cells, whereas wild-type p53 is strongly
downregulated in p53 wild-type colon cancer HCT116 cells in response to ERβ expression
[43]. Introduction of ERβ results in retention of p53 in the nucleus and subsequently increases
p53 transcriptional activity in p53 wild-type MCF7 cells [44]. Accordingly, the specific mecha-
nisms mediating the functional interactions between ERβ and p53 remain unclear. Further
clarification of the molecular relationships between ERβ and p53 could provide a rationale for
our finding that the double-positive expression of immunoreactive ERβ and p53 proteins is
closely associated with the incidence of regional lymph node metastasis and/or postoperative
recurrence.
In conclusion, we showed that increased expression of ERβ and p53 proteins in endometrial
endometrioid carcinoma was significantly correlated with the incidences of regional lymph
node metastasis and postoperative recurrence. Moreover, we demonstrated that positive stain-
ing of immunoreactive p53 protein including the low positive ranges (10–49%) was more
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effective as a clinical parameter than analysis of TP53 gene mutations. Although the number of
samples was small, the double-positive expression of immunoreactive ERβ and p53 proteins
may become a promising clinical parameter to predict the risk of lymph node metastasis and
postoperative relapse. Further clarification of the molecular relationship between ERβ and p53
may contribute to clarification of the mechanisms of endometrioid carcinoma progression
and yield more useful tools to predict the risk of progression in the future.
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